Quality of Care, Cost for Peripheral Arterial Disease Sufferers Not Equal

Cardiovascular

Author: Society of Interventional Radiology
Published: 2012/01/06 - Updated: 2014/03/14
Contents: Summary - Introduction - Main - Related

Synopsis: New study on peripheral arterial disease reveals quality of care and cost depend on who is providing the treatment.

Introduction

Study of More Than 14,000 Medicare Patients With Peripheral Arterial Disease Helps Consumers Navigate Medical Provider and Treatment Choice.

Main Digest

Although minimally invasive (endovascular) treatments for patients with peripheral arterial disease (PAD) result in shorter hospital stays and the potential to save Medicare millions of dollars each year, a new study reveals that the quality of care and cost depend on who's providing the treatment. The study, which appears in this month's Journal of Vascular and Interventional Radiology, is the first and largest study of its kind on these treatments for Medicare patients age 65 and older.

"Identifying quality health care and cost savings for treating a disease that affects millions of Americans is critical," said Marshall Hicks, M.D., FSIR, president-elect of the Society of Interventional Radiology, a national scientific organization of nearly 4,700 doctors, scientists and allied health professionals dedicated to improving health care through minimally invasive treatments. "This study can help consumers understand that different doctors get different outcomes for the same treatments and that they have a choice," said Hicks, an interventional radiologist and head of the diagnostic imaging division at the University of Texas MD Anderson Cancer Center in Houston.

PAD is a common yet dangerous condition that affects an estimated 10 million people in the United States (12-20 percent of Americans over age 65) and can lead to heart attack or stroke. The vascular disease develops mostly as a result of atherosclerosis or hardening of the arteries, which occurs when cholesterol and scar tissue build up, forming plaque that narrows and clogs the arteries and slows blood flow to the legs.

Researchers in the study reviewed Medicare claims data from more than 14,000 patients with PAD over two years from Medicare's Standard Analytical Files, which present a large dataset that contains all services (physician, inpatient, and outpatient). The authors compared outcomes of percutaneous (procedures done through the skin) PAD treatments in Medicare patients according to the physician specialty type (interventional radiologist, interventional cardiologist, vascular surgeon) that provided the service and assessed mortality, transfusion, intensive care use, length of stay, and subsequent restoration of blood supply or amputation. Outcomes were compared using standard outcome prediction formulas adjusted for age, gender, race, emergency department admission and other existing conditions.

"We found that costs and provider care are not alike," said current society president Timothy P. Murphy, M.D., FSIR, a study co-author. "We noted that the adjusted average one-year procedure cost when performed by interventional radiologists was about $17,640. That's a cost savings to Medicare of approximately $1,000 per procedure which means that in such a large population, treatments for PAD by interventional radiologists could potentially save taxpayers $230 million each year. And the patient outcomes are better," said Murphy, an interventional radiologist and director of the Vascular Disease Research Center at Rhode Island Hospital in Providence.

Murphy noted data from the study provided strong evidence that treatment by interventional radiologists provides numerous benefits to the PAD patient, such as less risk of infection, less anesthesia, less pain and scarring, faster recovery and a quicker return to normal activities. "The Medicare data clearly show more transfusion and intensive care utilization, longer length of stay, more repeat procedures or amputations and higher costs when treatment is not performed by interventional radiologists," Murphy added.

For more information about the Society of Interventional Radiology, peripheral arterial disease, minimally invasive treatments and the Journal of Vascular and Interventional Radiology, please visit online at www.SIRweb.org

Besides Murphy, co-authors of "Lower Extremity Endovascular Interventions for Medicare Beneficiaries: Comparative Effectiveness as a Function of Provider Specialty" include Abdul Mueed Zafar, M.D., University of Texas Health Sciences Center, San Antonio; Rajoo Dhangana, M.D., department of diagnostic imaging, Rhode Island Hospital, Brown University, Providence; Scott C. Goodwin, M.D., FSIR, department of radiology, University of California, Irvine; Richard Duszak Jr., M.D., FSIR, Baptist Memorial Hospital, Mid-South Imaging and Therapeutics, Memphis, Tenn.; Charles E. Ray Jr., M.D., Ph.D., FSIR, division of interventional radiology, University of Colorado, Aurora; and Nikolay E. Manolov, Ph.D., Lewin Group, Falls Church, Va.

Related Publications

Share This Information To:
𝕏.com Facebook Reddit

Page Information, Citing and Disclaimer

Disabled World is an independent disability community founded in 2004 to provide news and information to people with disabilities, seniors, their family and carers. We'd love for you to follow and connect with us on social media!

Cite This Page (APA): Society of Interventional Radiology. (2012, January 6 - Last revised: 2014, March 14). Quality of Care, Cost for Peripheral Arterial Disease Sufferers Not Equal. Disabled World. Retrieved July 16, 2024 from www.disabled-world.com/health/cardiovascular/29876.php

Permalink: <a href="https://www.disabled-world.com/health/cardiovascular/29876.php">Quality of Care, Cost for Peripheral Arterial Disease Sufferers Not Equal</a>: New study on peripheral arterial disease reveals quality of care and cost depend on who is providing the treatment.

Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.